Cargando…
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ patholog...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791759/ https://www.ncbi.nlm.nih.gov/pubmed/36567338 http://dx.doi.org/10.1186/s40035-022-00324-y |
_version_ | 1784859478790766592 |
---|---|
author | Bonvicini, Gillian Syvänen, Stina Andersson, Ken G. Haaparanta-Solin, Merja López-Picón, Francisco Sehlin, Dag |
author_facet | Bonvicini, Gillian Syvänen, Stina Andersson, Ken G. Haaparanta-Solin, Merja López-Picón, Francisco Sehlin, Dag |
author_sort | Bonvicini, Gillian |
collection | PubMed |
description | BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ pathology in mouse models of Alzheimer’s disease (AD). This study aimed to determine if this strategy would be as sensitive in rats and to assess how TfR affinity affects BBB transport of bispecific immunoPET radioligands. METHODS: Two affinity variants of the rat TfR antibody, OX26, were chemically conjugated to a F(ab′)(2) fragment of the anti-Aβ antibody, bapineuzumab (Bapi), to generate two bispecific fusion proteins: OX26(5)-F(ab′)(2)-Bapi and OX26(76)-F(ab′)(2)-Bapi. Pharmacokinetic analyses were performed 4 h and 70 h post-injection of radioiodinated fusion proteins in wild-type (WT) rats. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi was administered to TgF344-AD and WT rats for in vivo PET imaging. Ex vivo distribution of injected [(124)I]I-OX26(5)-F(ab′)(2)-Bapi and Aβ pathology were assessed. RESULTS: More [(125)I]I-OX26(5)-F(ab′)(2)-Bapi was taken up into the brain 4 h post-administration than [(124)I]I-OX26(76)-F(ab′)(2)-Bapi. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi PET visualized Aβ pathology with significantly higher signals in the TgF344-AD rats than in the WT littermates without Aβ pathology. The PET signals significantly correlated with Aβ levels in AD animals. CONCLUSION: Affinity to TfR affects how efficiently a TfR-targeting bispecific fusion protein will cross the BBB, such that the higher-affinity bispecific fusion protein crossed the BBB more efficiently. Furthermore, bispecific immunoPET imaging of brain Aβ pathology using TfR-mediated transport provides good imaging contrast between TgF344-AD and WT rats, suggesting that this immunoPET strategy has the potential to be translated to higher species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00324-y. |
format | Online Article Text |
id | pubmed-9791759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97917592022-12-27 ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein Bonvicini, Gillian Syvänen, Stina Andersson, Ken G. Haaparanta-Solin, Merja López-Picón, Francisco Sehlin, Dag Transl Neurodegener Research BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ pathology in mouse models of Alzheimer’s disease (AD). This study aimed to determine if this strategy would be as sensitive in rats and to assess how TfR affinity affects BBB transport of bispecific immunoPET radioligands. METHODS: Two affinity variants of the rat TfR antibody, OX26, were chemically conjugated to a F(ab′)(2) fragment of the anti-Aβ antibody, bapineuzumab (Bapi), to generate two bispecific fusion proteins: OX26(5)-F(ab′)(2)-Bapi and OX26(76)-F(ab′)(2)-Bapi. Pharmacokinetic analyses were performed 4 h and 70 h post-injection of radioiodinated fusion proteins in wild-type (WT) rats. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi was administered to TgF344-AD and WT rats for in vivo PET imaging. Ex vivo distribution of injected [(124)I]I-OX26(5)-F(ab′)(2)-Bapi and Aβ pathology were assessed. RESULTS: More [(125)I]I-OX26(5)-F(ab′)(2)-Bapi was taken up into the brain 4 h post-administration than [(124)I]I-OX26(76)-F(ab′)(2)-Bapi. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi PET visualized Aβ pathology with significantly higher signals in the TgF344-AD rats than in the WT littermates without Aβ pathology. The PET signals significantly correlated with Aβ levels in AD animals. CONCLUSION: Affinity to TfR affects how efficiently a TfR-targeting bispecific fusion protein will cross the BBB, such that the higher-affinity bispecific fusion protein crossed the BBB more efficiently. Furthermore, bispecific immunoPET imaging of brain Aβ pathology using TfR-mediated transport provides good imaging contrast between TgF344-AD and WT rats, suggesting that this immunoPET strategy has the potential to be translated to higher species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00324-y. BioMed Central 2022-12-26 /pmc/articles/PMC9791759/ /pubmed/36567338 http://dx.doi.org/10.1186/s40035-022-00324-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bonvicini, Gillian Syvänen, Stina Andersson, Ken G. Haaparanta-Solin, Merja López-Picón, Francisco Sehlin, Dag ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title_full | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title_fullStr | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title_full_unstemmed | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title_short | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
title_sort | immunopet imaging of amyloid-beta in a rat model of alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791759/ https://www.ncbi.nlm.nih.gov/pubmed/36567338 http://dx.doi.org/10.1186/s40035-022-00324-y |
work_keys_str_mv | AT bonvicinigillian immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein AT syvanenstina immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein AT anderssonkeng immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein AT haaparantasolinmerja immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein AT lopezpiconfrancisco immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein AT sehlindag immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein |